# Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

> **NCT02527746** · PHASE1 · COMPLETED · sponsor: **EVIVE Biotechnology** · enrollment: 18 (actual)

## Conditions studied

- Neutropenia
- Breast Cancer

## Interventions

- **DRUG:** F-627
- **DRUG:** EC regimen

## Key facts

- **NCT ID:** NCT02527746
- **Lead sponsor:** EVIVE Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02527746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02527746, "Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02527746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*